Indication
Dravet syndrome
23 clinical trials
16 products
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic EncephalopathiesStatus: Completed, Estimated PCD: 2023-11-16
Product
LP352Product
PlaceboClinical trial
A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 WeeksStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
EpidiolexClinical trial
WAYFINDER: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeStatus: Recruiting, Estimated PCD: 2029-12-01
Product
ETX101Clinical trial
A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)Status: Recruiting, Estimated PCD: 2024-06-30
Product
PRAX-562Product
CannabidiolClinical trial
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Expanded Access Treatment With LP352 for Patients With Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)Status:
Clinical trial
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)Status: Recruiting, Estimated PCD: 2024-12-19
Product
EPX-100Product
STK-001Clinical trial
An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet SyndromeStatus: Completed, Estimated PCD: 2023-12-13
Clinical trial
ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet SyndromeStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
EXPEDITION: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeStatus: Recruiting, Estimated PCD: 2029-12-01
Product
ZX008Clinical trial
A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome (Cohort 2)Status: Completed, Estimated PCD: 2018-06-05
Product
GWP42003-PProduct
Placebo ControlClinical trial
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet SyndromeStatus: Completed, Estimated PCD: 2023-01-27
Product
Matching PlaceboClinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.Status: Completed, Estimated PCD: 2018-04-09
Clinical trial
An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001Status: , Estimated PCD: 2026-02-03
Clinical trial
A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet SyndromeStatus: Completed, Estimated PCD: 2015-11-26
Clinical trial
An Exploratory, Pilot Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome: A Sub-study to the ZX008-1503 Open-Label Extension TrialStatus: Terminated, Estimated PCD: 2018-07-05
Product
Zx008Clinical trial
A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet SyndromeStatus: Completed, Estimated PCD: 2015-03-09
Product
FenfluramineClinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet SyndromeStatus: Completed, Estimated PCD: 2020-07-29
Clinical trial
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut SyndromeStatus: Completed, Estimated PCD: 2020-06-24
Clinical trial
The LEONIDaS(Long Term Exploration of Outcomes From New Interventions in Dravet Syndrome) Caregivers StudyStatus: Withdrawn, Estimated PCD: 2023-10-26
Product
MultipleClinical trial
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-06-28